"Our subspecialty-trained, board certified hematologists and oncologists provide patients with expertise in the treatment of cancer and blood disorders. With cutting-edge technology and a caring atmosphere, we do everything we can to help our patients with both initial diagnosis and the treatment that follows. Our offices are located in the Virginia K. Crosson Cancer Institute where we can conveniently provide most necessary services for our patients in one stop. As an integral part of the Virginia K. Crosson Cancer Center, we can offer today’s best improvements in care, including breakthroughs in immunology, biotherapy and targeted chemotherapy."

During the past decade, Virginia K. Crosson Cancer Center conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 14 clinical trials were completed, i.e. on average, 280% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia K. Crosson Cancer Center" #1 sponsor was "Novartis Pharmaceuticals" with 5 trials, followed by "Translational Oncology Research International" with 5 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "NSABP Foundation Inc" with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia K. Crosson Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 8 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "Bayer" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "University of California, Los Angeles" with 2 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Virginia K. Crosson Cancer Center" are "Breast Cancer" (8 trials), "Colonic Neoplasms" (2 trials), "Colorectal Cancer" (2 trials), "Colorectal Neoplasms" (2 trials) and "Metastatic Breast Cancer" (2 trials). Many other conditions were trialed in "Virginia K. Crosson Cancer Center" in a lesser frequency.

Most popular intervention types in "Virginia K. Crosson Cancer Center" are "Drug" (29 trials), "Biological" (4 trials), "Other" (4 trials), "Radiation" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Docetaxel" (3 trials), "Trastuzumab" (3 trials), "Bevacizumab" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Virginia K. Crosson Cancer Center" are 21 trials for "All" genders, 9 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Virginia K. Crosson Cancer Center". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Virginia K. Crosson Cancer Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia K. Crosson Cancer Center, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".